Catalyst Crew Technologies Corp. has submitted a corporate action request to the Financial Industry Regulatory Authority seeking approval for a proposed name change to LataMed AI Corp. and a corresponding change to its trading symbol. The move aims to better align the company's public identity with its strategic transition toward artificial intelligence-enabled healthcare technology.
The company's new focus encompasses healthcare analytics and technology-enabled healthcare services infrastructure, with an initial strategic emphasis on Latin America. According to the announcement, the proposed corporate action was approved by the company's Board of Directors and by written consent of the majority shareholder in accordance with Nevada law. The company clarified that the change does not involve any reverse stock split, forward stock split, recapitalization, or modification to its capital structure, and the issued and outstanding share count will remain unchanged.
Dr. Kevin Rodan Levy, Chief Executive Officer of Catalyst Crew Technologies Corp., stated that the proposed name change is intended to better align the company's public identity with its healthcare technology strategy and long-term market focus. He emphasized that there is no change to the company's capital structure as part of this process. The name and symbol change will not affect shareholders' ownership interests, and no action will be required by existing shareholders.
Upon FINRA approval, the company intends to file a Certificate of Amendment with the Nevada Secretary of State to effect the corporate name change. The proposed changes would become effective upon completion of required corporate filings and publication by FINRA on the Daily List. However, the company noted that no assurance can be given that FINRA will approve the proposed name change, the requested new trading symbol, or the timing of any such approval.
For business and technology leaders monitoring emerging market opportunities, this rebranding signals a strategic pivot toward addressing healthcare infrastructure gaps in Latin America through AI and digital health solutions. The company describes itself as an artificial intelligence-driven healthcare technology company focused on developing scalable digital health solutions for emerging markets, with initiatives spanning telehealth infrastructure, remote patient monitoring, healthcare data analytics, and integrated digital care platforms. More information about the company's strategy can be found at https://catalystcrewai.com, and investors can review the company's filings with the U.S. Securities and Exchange Commission at https://www.sec.gov.
The company acknowledges it is a development-stage enterprise that has not generated revenues from its newly announced business direction, and there can be no assurance it will successfully implement its business plan, complete acquisitions, secure financing, obtain regulatory approvals, or generate revenues. This rebranding represents a calculated effort to position the company within the growing AI healthcare sector while targeting a region with significant demand for modernized healthcare delivery systems.
